Category Archives: Myocardial Infarction

Global Fibrinolytic Therapy Market Research Report offers a in-depth view on market trends, forecast statistics, company profile, growth drivers and latest industry insights. The report covers all the Fibrinolytic Therapy type, applications, deployment models, research regions Continue reading →

Aims:There are sex differences in presentation, treatment, and outcomes of myocardial infarction (MI) but less is known about these differences in a younger patient population. The objective of this study was to investigate sex differences among individuals who experience their first MI at a young age. Continue reading →

Anti-inflammatory therapy with canakinumab was found to reduce the total number of cardiovascular events in patients with prior myocardial infarction and evidence of residual inflammatory risk, according to a published study in the Journal of the American College of Cardiology. A total of 10,061 patients with a prior history of myocardial infarction and a high-sensitivity C-reactive protein (hsCRP) levels 2 mg/L were enrolled in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS; ClinicalTrials.gov Identifier: NCT01327846). Participants were randomly assigned to received placebo or the interleukin (IL)-1 inhibitor canakinumab at 50 mg, 150 mg, or 300 mg once every 3 months Continue reading →

Results of an Individual Patient Data Pooled Analysis Reported at TCT Connect NEW YORK October 15, 2020 An individual patient data pooled analysis comparing the use of bivalirudin versus heparin in heart attack patients undergoing percutaneous coronary intervention (PCI) found that bivalirudin use was associated with similar overall rates of 30-day mortality across all heart attack patients, but lower rates of serious bleeding events. Moreover, mortality was reduced in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with a post-PCI bivalirudin infusion. Findings were reported today at TCT Connect, the 32ndannual scientific symposium of the Cardiovascular Research Foundation (CRF). Continue reading →

Vanderbilt University Medical Centers Acute Myocardial Infarction, Discharged Alive MSPB average increased by almost 13% Want a Demo of Dexur's full capabilities? By: Parvathy Rajagopal &nbspOct. 16, 2020 Dexur analyzed Medicare Claims data and replicated CMS algorithms to calculate Medicare Spending per Beneficiary (MSPB) cost per episode of Vanderbilt University Medical Center and found that the cost per episode was $33,526 for Acute Myocardial Infarction, Discharged Alive, from Jan-Dec 2019. Continue reading →

Global Post-Myocardial Infarction Market: Overview The most common term used to refer to myocardial infarction is heart-attack. In this report, TMR Research (TMR) delves into studying the factors causing the demand for post-myocardial infarction treatment. For the purpose of the study, TMR thus segments the global post-myocardial infarction market based on various parameters and then identifies opportunities prevalent across each of these segments. Continue reading →

Sophia Antipolis, Octobe 15, 2020: One in five high-risk patients undergoing major non-cardiac surgery will develop one or more heart complications within a year, according to research published today inEuropean Heart Journal Acute Cardiovascular Care, a journal of the European Society of Cardiology (ESC).1 Our study reveals a greater likelihood of having heart problems or dying after non-cardiac surgery than has been recognised to date, said study author Dr. Christian Puelacher of the University of Basel, Switzerland. Continue reading →

KANAGAWA, Japan (PRWEB) October 15, 2020 The non-clinical studies conducted by Metcela revealed at least two clear subpopulations of fibroblasts found in the human fetal heart: VCAM1-positive cardiac fibroblasts (VCFs) and VCAM1-negative cardiac fibroblasts (VNCFs). When examined with bioinformatics analyses, VCFs expressed numerous genes related to lymphatic vessel formation Continue reading →

For immediate release: October 12, 2020 Boston, MA The hospitalization rate for acute cardiovascular disease (CVD) events in a large southern California health system was 1.62 times higher in the two days immediately after the 2016 presidential election when compared with the same two days in the week prior to the 2016 election, according to new research from Harvard T.H. Chan School of Public Health and Kaiser Permanente. The results were similar across sex, age, and race and ethnicity groups, and the findings suggest that sociopolitical stress may trigger CVD events Continue reading →

1. In trauma patients at risk for hemorrhage, pre-hospital administration of tranexamic acid did not significantly improve 30-day mortality compared to a placebo Continue reading →